Asthma patients face new challenges as BCBS Texas changes treatment policies
Uncontrolled asthma in texans led to more than 1-hundred 15-thousand emergency department visits in 20-18 -- according to texas health and human services.Dr. Am ...
Severe Asthma FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight
The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology ...
Science Daily8h
Molecular basis of food allergy
A multi-institutional study has identified one of the allergens responsible for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus. This is the first time one of the allergens ...
Novel study uncovers molecular basis of eosinophilic esophagitis food allergy
A multi-institutional study led by researchers at Children's Hospital of Philadelphia (CHOP) is the first to identify one of ...
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb.
GSK announces EMA accepted for review the MAA for depemokimab
GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...
Zacks.com on MSN6d
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...
Daily6d
GSK Depemokimab accepted for review by EMA for use in asthma with type 2 inflammation, CRSwNP
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications.The ...